Novavax | NVAX - Current Liabilities


Novavax reported $342.46M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Adma Biologics USD 73.54M 4M Mar/2026
Agenus USD 249.24M 74.25M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Cassava Sciences USD 40.11M 3.72M Mar/2026
Geron USD 73.57M 40.25M Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
MannKind USD 134.56M 36.47M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Moderna USD 2.4B 408M Mar/2026
Novartis USD 27.28B 4.72B Dec/2025
Novavax USD 342.46M 117.49M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Sanofi EUR 30.01B 1.66B Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
TG Therapeutics USD 187.11M 33.35M Mar/2026